Skip to main content

Big fall in Rupee against Dollar, What next? डॉलर के मुकाबले रुपये में बड़ी गिरावट, आगे क्या? fall in Rupee against Dollar, What next? डॉलर के मुकाबले रुपये में बड़ी गिरावट, आगे क्या?

 

WHAT  HAS HAPPENED?

On Wednesday, the rupee fell sharply by 105 paise-its biggest single session fall in 20 months-to close at a five-month low of 74-47 against the US dollar, Amid concerms over Covid-19 and the RBT's newly announced programme to buy bonds worth Rs 1 lakh crore this quarter.
These factors come on top of a strengthening dollar against the euro, which is resulting in a relative weakness of the rupee.


RUPEE- IN LAST 1 YEAR

Aher peaking at around 77 against the US dollar on April 21 last year, the rupee started appreciating and reached 72.27 on March 23 this year, The move to 77 had been preceded by a sharp rally in the dollar index before the Covid-19 pandemie hit the global economy; Since then, the gradual appreciation was underpinned by a fall in the dollar index, and a strong flow of foreign direct investment and foreign portfolio investment FPl inflows in FY21 amounted to over $35 billion.

WHAT NEXT?

Since Mareh 23, the rupee has been depreciating amid concerns over Covid and the RBI policy announcement.
Many currency traders and analysts argue that Wednesday sharp, abrupt fall cannot be a "false signal"; They expect the rupee to head back to levels of 77-78 over the next few months.

Nitesh Sharma, founder and director of Routeforex Solutions Pt Ltd said,

"Rupee is expected to depreciate gradually to levels of 76.5 to 77 in three to four months, As rising Covid numbers have dampened market sentiment and it has also been impacted by RBI's programme to buy government securities worth Rs 1 lakh erore this quarter.

G-SAP?

The newly announced programme, called G-SAP, is being read as a sort of quantitative easing8 policy, In which the RBI tries to support the government's elevated borrowing programme through infusion of liquidity. This, along with a rising dollar, is ereating grounds for the
rupee to depreciate further.

WILL THE RBI INTERVENE?


The general feeling among experts is that the RBI may not intervene if the depreciation is gradual, but may do so if there is a big volatility. "Since we think that exports will rise, RBI will be comfortable

with any depreciation and would not step in. While they may step in for high volatility, they would not step in for a gradual decline," said Sabnavis,


HOW CAN THE RUPEE DEPRECIATION IMPACT YOU?

Depreciation in the rupee impacts all expenditure in dollar terms-imports, foreign education, travel, investments
abroad, medical treatment etec. On the other hand, if you are an exporter or an NRI sending money back home, depreciation would fetch you more rupees per dollar,


क्या हुआ है?

 बुधवार को अमेरिकी डॉलर के मुकाबले 74.47 के पांच महीने के निचले स्तर पर बंद होने के 20 महीनों में रुपया 105 पैसे की गिरावट के साथ सबसे बड़ा एकल सत्र गिर गया।  इस तिमाही में 1 लाख करोड़ रु।
 ये कारक यूरो के मुकाबले एक मजबूत डॉलर के ऊपर आते हैं, जिसके परिणामस्वरूप रुपये की सापेक्ष कमजोरी होती है।

 


 पिछले 1 वर्ष में रुपए

 पिछले साल 21 अप्रैल को अमेरिकी डॉलर के मुकाबले लगभग 77 की रफ्तार से आगे बढ़ता हुआ, रुपया सराहना करने लगा और 72.27 तक पहुंच गया
 इस वर्ष 23 मार्च को, 77 के कदम को डॉलर सूचकांक में तेज रैली से पहले कोविद -19 महामारी ने वैश्विक अर्थव्यवस्था को मारा था;  तब से, डॉलर इंडेक्स में गिरावट के कारण धीरे-धीरे प्रशंसा को कम किया गया था, और विदेशी प्रत्यक्ष निवेश और विदेशी पोर्टफोलियो निवेश एफपीएल का मजबूत प्रवाह वित्तीय वर्ष 21 में $ 35 बिलियन से अधिक था।

 आगे क्या?

 23 मार्च के बाद से, रुपये कोविद और आरबीआई नीति घोषणा पर चिंताओं के बीच मूल्यह्रास कर रहा है।
 कई मुद्रा व्यापारियों और विश्लेषकों का तर्क है कि बुधवार तेज, अचानक गिरावट "गलत संकेत" नहीं हो सकता है;  उन्हें अगले कुछ महीनों में रुपया 77-78 के स्तर तक पहुंचने की उम्मीद है।

 नीतेश शर्मा, जो रूटफ्रॉक्स सॉल्यूशंस पीटी लिमिटेड के संस्थापक और निदेशक हैं।

 "रु। तीन से चार महीनों में धीरे-धीरे 76.5 से 77 के स्तर तक घटने की उम्मीद है, क्योंकि कोविद की बढ़ती संख्या ने बाजार की धारणा को प्रभावित किया है और यह आरबीआई के कार्यक्रम से प्रभावित हुआ है, जिसने इस तिमाही में 1 लाख रुपये की सरकारी प्रतिभूतियां खरीदी हैं।

 जी-एसएपी?


 जी सैप नामक नए घोषित कार्यक्रम को मात्रात्मक सहजता 8 नीति के रूप में पढ़ा जा रहा है, जिसमें आरबीआई तरलता के जलसेक के माध्यम से सरकार के उन्नत उधार कार्यक्रम का समर्थन करने की कोशिश करता है।  यह, एक बढ़ते डॉलर के साथ, के लिए आधार गिर रहा है आगे मूल्यह्रास के लिए रुपया।


 क्या आरबीआई इंटरवेंन होगा?


 विशेषज्ञों के बीच सामान्य भावना यह है कि मूल्यह्रास क्रमिक होने पर आरबीआई हस्तक्षेप नहीं कर सकता है, लेकिन बड़ी अस्थिरता होने पर ऐसा कर सकता है।  "चूंकि हमें लगता है कि निर्यात बढ़ेगा, इसलिए आरबीआई सहज होगा

 सबनवीस ने कहा, "वे किसी भी मूल्यह्रास के साथ कदम नहीं रखेंगे। हालांकि वे उच्च अस्थिरता के लिए कदम बढ़ा सकते हैं, लेकिन वे क्रमिक गिरावट के लिए कदम नहीं रखेंगे।"


 आप कैसे  रुपए का नुकसान को कम कर सकते है ?

 रुपये में मूल्यह्रास डॉलर के संदर्भ में सभी खर्चों-आयात, विदेशी शिक्षा, यात्रा, निवेश को प्रभावित करता है विदेश में, चिकित्सा उपचार इत्यादि।  दूसरी ओर, यदि आप एक निर्यातक या एनआरआई हैं, जो घर वापस पैसा भेज रहे हैं, तो मूल्यह्रास आपको प्रति डॉलर अधिक रुपये प्राप्त होगा,

Comments

Popular posts from this blog

Mystery brain disease found in Canada

  WHAT HAS HAPPENED? An unknown brain disease has caused panic in the New Brunswick province of Canada after a string of cases were reported that involved memory loss, hallucinations and muscle atrophy. People living in the province became cognizant of the disease after a memo from the province's public health agency leaked last week, Which asked doctors to look for symptoms relate to Creutzfeldt-Jacob disease (CJD). CJD is a rare brain disease which is caused due to abnormally folded proteins called prions. Creutzfeldt-Jakob (KROITS-felt YAH-kobe) disease (CJD) is a degenerative brain disorder that leads to dementia and, ultimately, death. Creutzfeldt-Jakob disease symptoms can be similar to those of other dementia-like brain disorders, such as Alzheimer's disease. But Creutzfeldt-Jakob disease usually progresses much more rapidly. Transmitted by contact with infected tissue, such as during a transplant or from eating contaminated meat. CAUSES NOT KNOWN FOR CURRENT DISE...

ANDHRA PRADESH STRAIN 15 TIMES MORE VIRULENT

  Experts are saying that a new Andhra Pradesh variant of the SARS-COV-2 virus is at least 15 times more virulent than the earlier ones. May be even stronger than the Indian variants of B. 1.617 and B. 1.618 . Speculation is still on regarding whether it is a new strain or the old N440K. The N440K variant was first discovered by Centre for Cellular and Molecular Biology (CCMB).However, data is still insufficient to confirm anythin. The impact of AP Strain Authorities say that the variant at present which is in circulation in Visakhapatnam is different from what we have seen during the first wave last year. Samples have been sent to CCMB for analysis, in order to find out which strain is in circulation right now.It has been observed that the new variant has shorter incubation period and the progress of the disease is much rapid. In the earlier cases, a patient infected with the virus would take at least a week to reach the hypoxia or dyspnea stage. But in the present context,...

Anti-Covid drug developed by DRDO

  WHAT HAS HAPPENED? The Drugs Controller General of India (DCG) has approved the emergency use of Drug 2-deoxy-D-glucose (2-DG) as an adjunet therapy in moderate to severe Covid-19 patients. WHO DEVELOPED IT? The Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of Defence Research and Development Organisation (DRD0), has developed the drug, In collaboration with Dr Reddy's Laboratories, Hyderabad. WHEN & HOW IT WAS DEVELOPED? In April 2020 , during the first wave of the pandemic, INMAS-DRDO scientists conducted laboratory experiments with the help of Centre for Cellular and Molecular Biology (CCMB), Hyderabad and Found that this molecule works effectively against SARS-CoV-2 virus and inhibits the viral growth. Based on these results, Drugs Controller General of India's (DCG) Central Drugs Standard Control Organization (CDSCO) permitted Phase-II clinical trial of 2-DG in COVID-19 patients in May 2020 . The DRDO, along with its industry partner DRL, Hyd...